Press Release Archive

May 25, 2011 - Pfizer Announces New Strategic Partnerships With ICON And PAREXEL International Corporation

(BUSINESS WIRE)--Pfizer Inc. today announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011. The new partnerships will be fully implemented over an 18-to-24 month period. The ICON and PAREXEL alliances reflect Pfizer’s recent commitment to strengthen the performance of

May 24, 2011 - Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions

(BUSINESS WIRE)--Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS

May 24, 2011 - Pfizer Announces Detailed Results Of ORAL Sync Showing Investigational Compound Tofacitinib Reduces Signs And Symptoms And Improves Physical Function In Patients With Moderate-To-Severe Active Rheumatoid Arthritis, With Results Seen As Early As Two Weeks

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced data from ORAL Sync (A3921046) and Study A3921109, two clinical trials of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor, being studied in rheumatoid arthritis (RA). Top-line results of ORAL Sync, a pivotal Phase 3 trial, were announced earlier this year. A separate trial, Study A3921109, evaluated the safety and efficacy of atorvastatin versus

May 21, 2011 - Adding Inspra® (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard therapy. This analysis was a pre-

May 20, 2011 - SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors

(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.1,2 “We are delighted that

May 20, 2011 - ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

(BUSINESS WIRE)--PRINCETON, N.J.

May 18, 2011 - Pfizer Presents New Phase 3 Data Showing Axitinib Significantly Extended Progression-Free Survival Compared With Sorafenib In Patients With Previously-Treated Advanced Renal Cell Carcinoma

(BUSINESS WIRE)--Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95%CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population. PFS

May 16, 2011 - Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare

(BUSINESS WIRE)--Pfizer Inc. announced today that its New Drug Application (NDA) for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA) and has been filed with the Japanese Ministry of Health, Labour and Welfare (MHLW). The proposed indication is for the treatment of patients with ALK-positive advanced non

May 15, 2011 - Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting

(BUSINESS WIRE)--Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,1 crizotinib,2 and bosutinib,3 as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,4,5 at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. The Company will also share analyses from early stage compounds focused on the science behind tumor

May 10, 2011 - Pfizer Animal Health And American Humane Association Partner To Conduct Research On The Power Of The Human-Animal Bond In Pediatric Cancer Patients

(BUSINESS WIRE)--Pfizer Animal Health and American Humane Association today announced a partnership to conduct a study on the impact of animal-assisted therapy on pediatric oncology patients, as well as on their parents, caregivers, siblings, and other close family members. The partnership — which includes a $282,000 grant from Pfizer and the Pfizer Foundation — exemplifies the strategic goal of both organizations to better

May 9, 2011 - Alzheimer’s Association Salutes Advocate And Mountaineer Now Climbing Everest As Part Of The 7 Summits Climb For Alzheimer’s

(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the Alzheimer’s Association™, the world's leading voluntary health organization in Alzheimer's care, support and research, as a new beneficiary of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. Through this campaign, mountaineer and Alzheimer’s disease advocate

May 8, 2011 - Pfizer’s Prevnar 13® Meets All Study Endpoints In Two Pivotal Phase 3 Trials In Adults Aged 50 And Older Presented Today

(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 years and older met all study endpoints. These studies provide the clinical foundation for the regulatory filings that have been submitted in the United States, the European Union and more than a dozen other

May 4, 2011 - The European Commission Approves Pfizer’s Revatio® (sildenafil) for the Treatment of Pulmonary Arterial Hypertension in Children

(BUSINESS WIRE)--Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. “Pulmonary arterial

May 3, 2011 - PRISTIQ® (desvenlafaxine) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ® (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington

May 2, 2011 - Pfizer Reports First-Quarter 2011 Results

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) First-Quarter 2011 2010 Change

May 2, 2011 - Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2011 Healthcare Conference on Tuesday, May 10, 2011 at 11:20 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of

May 1, 2011 - Centrum® multivitamins and Celebrity Personal Trainer Harley Pasternak Share Star-Tested Secrets to Shape up for Summer

(BUSINESS WIRE)--It’s not what celebrities know about getting fit for summer, it’s who they know. And when Hollywood stars want to get in the best shape of their lives, they call Harley Pasternak, creator of the 5 Factor Diet. This spring, the makers of Centrum® multivitamins are teaming up with Pasternak to bring star-worthy tips to Americans. One lucky person will win a trip to Los Angeles and a training session with Harley, a renowned

April 28, 2011 - Pfizer Hosts Annual Meeting of Shareholders

(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 20-cent second-quarter 2011 dividend on the company’s common stock, payable June 7, 2011, to shareholders of record at the close of business on May 13, 2011. The second-quarter 2011 cash dividend will be the 290th consecutive quarterly dividend paid by Pfizer. “Through dividends and share repurchases, we returned approximately $7.1 billion to our shareholders in

April 27, 2011 - Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Standard (A3921064) and ORAL Step (A3921032) Phase 3 studies of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor. ORAL Standard is a completed twelve-month study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive

April 26, 2011 - Pfizer Launches New Advanced GOLD Range Of Early Child Nutrition Products

"By drawing upon Pfizer’s innovative science core, we are now introducing the first of a series of clinically-based nutrition products that help provide the optimal nutrients for children."

Press release archive foot note

Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.

Stay on top of Pfizer breaking news: Get News Alerts by RSS.

Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.

If you do not have Adobe^® Reader, download it here. It is available without charge from Adobe^®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.